Advertisement

Topics

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015

02:28 EDT 22 Jul 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-06-16. This 247-page report is available in PDF from $2000.

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015’, provides an overview of the Relapsed Chronic Lymphocytic Leukemia (CLL)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Relapsed Chronic Lymphocytic Leukemia (CLL)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Relapsed Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Relapsed Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Relapsed Chronic Lymphocytic Leukemia (CLL) Overview 11
Therapeutics Development 12
Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Overview 12
Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis 13
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 14
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 18
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 21
Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 24
Relapsed Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 25
4SC AG 25
AbbVie Inc. 26
Astellas Pharma Inc. 27
Astex Pharmaceuticals, Inc. 28
AstraZeneca Plc 29
Boehringer Ingelheim GmbH 30
Bristol-Myers Squibb Company 31
Celgene Corporation 32
Emergent BioSolutions Inc. 33
F. Hoffmann-La Roche Ltd. 34
Genmab A/S 35
Gilead Sciences, Inc. 36
GlaxoSmithKline Plc 37
ImmunoGen, Inc. 38
Immunomedics, Inc. 39
Infinity Pharmaceuticals, Inc. 40
Innate Pharma SA 41
Juno Therapeutics Inc. 42
Karyopharm Therapeutics, Inc. 43
Les Laboratoires Servier SAS 44
LFB S.A. 45
MedImmune, LLC 46
Millennium Pharmaceuticals, Inc. 47
MorphoSys AG 48
Neopharm Ltd. 49
Novartis AG 50
Ono Pharmaceutical Co., Ltd. 51
Portola Pharmaceuticals, Inc. 52
Sanofi 53
TG Therapeutics, Inc. 54
Threshold Pharmaceuticals, Inc. 55
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 56
Assessment by Monotherapy Products 56
Assessment by Combination Products 57
Assessment by Target 58
Assessment by Mechanism of Action 61
Assessment by Route of Administration 63
Assessment by Molecule Type 65
Drug Profiles 67
4SC-202 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ACP-196 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
afuresertib hydrochloride - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
AGS-67E - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
AT-7519 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
AZD-6738 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
BI-836826 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
BMS-986016 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
buparlisib…

For more information open Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015.

SKU: GMDHC6699IDB

Original Article: Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...